Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Fund and Insider Trading News: Steve Cohen, Tom Steyer, Landec Corporation (LNDC), Genomic Health, Inc. (GHDX), and More

Insider Trading Charges Filed Against Pharma Company Accountant, Three Others (HedgeCo.Net)
(HedgeCo.Net) On March 19, 2019, the Securities and Exchange Commission obtained final judgments against a pharmaceutical company accountant and three tippees in an insider trading scheme. The SEC charged Evan R. Kita, Daniel Perez, Richard Yu, and Chiang Yu on August 31, 2017, alleging that Kita, a CPA and former accountant at Celator Pharmaceuticals Inc., provided confidential information about the company to Perez and Richard Yu, who purchased Celator stock based on Kita’s tips and agreed to share their trading profits with Kita. The SEC further alleged that Richard Yu passed the tips to his father, Chiang Yu, who also traded. According to the complaint, to avoid detection, Kita communicated with Perez and Richard Yu through an encrypted smartphone application.

Sun Pharma’s Senior Executive, Wife Settle Insider Trading Case With SEBI (Bloomberg)
Sun Pharmaceutical group’s Senior Executive Abhay Arvind Gandhi and his wife Kiran have settled a case with the Securities and Exchange Board of India related to insider trading in shares of Ranbaxy Laboratories Ltd. in 2014. Both paid a total of over Rs 70 lakh as settlement charges. At the time of alleged violation, Abhay Arvind Gandhi was the chief executive officer of Sun Pharma Laboratories Ltd., a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd.

FSCA Finds No Proof of Insider Trading at Steinhoff (eNCA)
JOHANNESBURG – The South African Financial Sector Conduct Authority says while investigations are still ongoing, it’s found no evidence of insider trading in Steinhoff’s shares before its stock collapsed. Bloomberg previously reported that former CEO Markus Jooste tipped friends to sell off the company’s shares days before the stock crashed in late November 2017. He apparently warned them of impending, bad news.

What Did This CEO Just Do with Personal Shares of Genomic Health (NASDAQ: GHDX)? (AnalystRatings)
Yesterday, the President & CEO of Genomic Health (GHDX), Kimberly Popovits, sold shares of GHDX for $166.5K. This is Popovits’ first Sell trade following 9 Buy transactions. In addition to Kimberly Popovits, one other GHDX executive reported Sell trades in the last month. Based on Genomic Health’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $105 million and quarterly net profit of $8.91 million. In comparison, last year the company earned revenue of $92.63 million and had a GAAP net loss of $3.78 million. GHDX’s market cap is $2.44B and the company has a P/E ratio of 101.58. Currently, Genomic Health has an average volume of 530.7K.

Thursday 4/11 Insider Buying Report: LNDC, OTEL (Nasdaq.com)
On Tuesday, Landec’s Director, Nelson Obus, made a $310,000 buy of LNDC, purchasing 30,000 shares at a cost of $10.33 a piece. So far Obus is in the green, up about 2.1% on their buy based on today’s trading high of $10.55. Landec is trading up about 0.1% on the day Thursday. Before this latest buy, Obus bought LNDC at 3 other times during the past twelve months, for a total investment of $630,540 at an average of $11.92 per share. And at Otelco, there was insider buying on Wednesday, by Ira Sochet who purchased 7,341 shares for a cost of $17.08 each, for a total investment of $125,419. Before this latest buy, Sochet purchased OTEL on 18 other occasions during the past twelve months, for a total investment of $5.71M at an average of $15.58 per share. Otelco is trading off about 0.7% on the day Thursday.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...